A series of novel imidazobenzodiazepine analogs of the lead chiral ligand SH-053-2'F-S-CH 3 (2), an α2/α3/α5 (Bz)GABA (A)ergic receptor subtype selective ligand, which reverses PCP-induced prepulse inhibition (PPI) of acoustic startle, were synthesized. These chiral (S)-CH 3 ligands are targeted for the treatment of schizophrenia and depression. These new ligands were designed by modifying the labile ester functionality in 2 to improve the metabolic stability, cytotoxicity, and activity as compared to 2. Based on the data to date, the most promising ligands are the N-cyclopropyl amide GL-I-55 (8c) and the methyl bioisostere GL-I-65 (9a). The in vitro metabolic stability, cytotoxicity and in vivo locomotor effects are described in this report. Based on these results, 8c and 9a are the most promising for further in vivo pharmacology.
Introduction

053-2'F-R-CH
(1) was the lead stereospecific GABA A R α5-subtype selective positive allosteric modulator (PAM) because of the (R)-methyl group at the C-4 position of imidazobenzodiazepine (IBZD), as shown in Figure 1 . This resulted in increased potency at α5 GABA A receptor subtypes accompanied by a concomitant decrease at an α1, α2, and α3 subtypes. This α5-selective ligand has been reported to successfully alleviate the hyperactivity of the dopamine system induced by amphetamine in the methylazoxymethanol acetate model (MAM) of schizophrenia. 24, 25 Moreover, ligand 1 in an animal behavioral model of depression exhibited anxiolytic and antidepressant effects in female mice that were exposed to unpredictable chronic mild stress (UCMS) in a sex-dependent manner. The effects on male mice in the same paradigm were very weak or none at all. 26 Furthermore, analogs of 4(R)-CH 3 enantiomer 1, such as the methyl amide MP-III-022, 27 the carboxylic acid SH-053-2'F-R-CH 3 -acid 28 , etc., which are more potent at the α5-subtype than 1, have also been investigated and undergone a number of behavioral studies. In order to study how the chirality at the C-4 position of IBZD could affect the pharmacological response, the enantiomer of 1, SH-053-2'F-S-CH 3 (2) was synthesized. 18 As expected, these two enantiomers exhibited vastly different GABAergic efficacy and binding affinity at Bz/GABA(A) receptor sites. Ligand 2 was found to be an α2-, α3-, α5-β3γ2 subtype selective, while 1 was an α5-subtype selective ligand. Since 1 and 2 both target the α5-subunit, they have been assayed in several behavioral models. Examination of the results revealed that 2 exerted anxiolytic effects in both rhesus monkeys 31 and rats, 32 while 1 had only a minimal anxiolytic effect when much higher doses were applied. Interestingly, 2 also successfully mitigated the amphetamine-induced hyperactivity in a poly (I:C) animal model of schizophrenia. 33 The results of these studies indicated that both enantiomers may be useful in the treatment of the symptoms of schizophrenia, while the α2/3/5 agonist 2 exhibited the potential for treatment of conditions comorbid with schizophrenia, such as anxiety, which commonly coexists in patients with schizophrenia. Unfortunately, during other studies, ligand 2 was shown to be metabolized at a very high rate in vitro in the presence of human liver microsomes (HLM), 34 only 3% of 2 remaining after incubation at 37 o C for 30 minutes, while ligand 1 was stable in HLM with 100% remaining under the same conditions, as presented in Table 1 . The principal aim of this research was to improve the metabolic stability of the ester functional group while retaining the properties potentially useful for the treatment of schizophrenia and depression. Schizophrenia and some forms of depression (bipolar I disorder and perhaps major depressive disorder) are linked both genetically and etiologically. Herein we present the synthesis and characterization of novel analogs of SH-053-2'F-S-CH 3 (2) including esters, thioesters, amides, carboxylic acids and the ester bioisostere oxadiazoles at the C(3) position together with modifications at the C(8) position. The newly designed ligands were prepared and investigated in in vitro metabolism studies, cytotoxicity assays and in vivo in mice with a rotarod study to 
Results and Discussion
Previously, evidence from the ligand-based GABA A R pharmacophore/receptor model and SAR 23, 35 have indicated that subtle changes in the IBZD substituents affect the BzR/GABA(A)R subtype selectivity dramatically. For instance, loss of the methyl group at the C(4) position decreases the α5-subtype efficacy while the efficacy at α2/α3-β3γ2 GABA(A)ergic subtypes increases dramatically. Efficacy at the α1 subtype increases with a 2'-F substituent on the C(6) pendent phenyl ring, but the 2'-N and 2'-H analogs remain α2/α3 subtype selective. 30 It has also been shown that the α5 selectivity can be modified by the presence of different lipophilic groups at the C(8) position. 19 Analogs, which have been optimized at the C(3) position, demonstrated higher affinity and potency at α5-36 or α2/3-37-39 subtypes leading to better and longer physiological effects.
For these reasons, the C(3) and C(8) positions are considered to be the optimal regions for ligand improvement. To evaluate the modification of the lead compound 2 at these two positions, a series of novel analogs were designed, synthesized and characterized, as summarized in Figure 2 . As mentioned earlier, the C(8)-acetylene and C(4) methyl function were found to enhance the α5-subtype selectivity, therefore a cyclopropyl group, which is commonly incorporated into biologically active materials, was introduced into the parent compound 2 as a substituent to extend the SAR. As the result of its flexible rotation at the C(8) position, it should fill a similar volume of electron density as the ethynyl moiety. Consequently, it might exhibit parallel physiological effects and enhanced subtype selectivity due to similar interactions in the lipophilic binding pocket (L2, see Figure S1 in Supplementary material for the model). 22 Moreover, metabolism by liver microsomes would be expected to be different for a cyclopropyl substituent as compared to an ethynyl functional group. Hence, the C(8)-substituted cyclopropyl analog GL-I-78 (3) was prepared based on this hypothesis. The cyclopropyl ligand 3 was synthesized from cyclopropyl boronic acid via a Suzuki cross-coupling reaction 40 with the aryl bromide SH-I-48B (4b), the synthesis of which had been previously described. 17 The coupling reaction was carried out in the presence of potassium phosphate and 10 mol% Pd-catalyst, bis(triphenylphosphine)palladium(II) diacetate, in toluene at 100 o C for 12 hours in good yield (82%), as shown in Scheme 1. 
17
Based on the results described previously, the ethyl ester 2 was rapidly degraded in the HLM, which suggests that modification of the ester might play an essential role in metabolism, as well as efficacy, as compared to the lead compound 2. Therefore, a series of esters, with different alkyl groups were synthesized. The synthesis of the C(8)-bromo methyl ester MP-III-059 (4a) and the C(8)-ethynyl methyl ester MP-III-021 (5a) were achieved in the presence of sodium methoxide in methanol in good yields, as depicted in Scheme 2. The majority of the reactions were carried out via a transesterification reaction 41 with pieces of freshly cut lithium rod in the presence of alcohols in THF at 40 o C for 0.5 hours to generate the corresponding alkoxides. To this solution, ester 2 was added, dissolved in dry THF, and full conversion was observed after 15 to 30 minutes. New ester analogs generated via this general route were: propyl ester GL-I-32 (5b), isopropyl ester GL-I-31 (5c), t-butyl ester GL-I-30 (5d) and 2-methylbutyl ester GL-I-33 (5e), respectively. The yields were good to excellent (77-97%), as illustrated in Scheme 3. However, the trifluoroethyl ester GL-I-36 (5f), and the cyclopropyl ester GL-I-38 (5g) were not obtained under these conditions. As a result, both analogs were prepared by an alternate procedure. The ester 2 was saponified to form the carboxylic acid, SH-053-2'F-S-CH 3 -acid (6), with sodium hydroxide in ethanol at reflux for 1 hour in nearly quantitative yield (99%) after acidic work-up, as illustrated in Scheme 4. The subsequent reactions for the synthesis of ester 5f and 5g were conducted with thionyl chloride in dichloromethane at reflux to give the acyl chloride, which was converted into esters 5f and 5g with 2,2,2-trifluoroethanol and cyclopropanol, respectively. Additionally, it must be pointed out that the acid 6 was synthesized not only because it was an important intermediate for the majority of the analogs, but also because the enantiomer (R)-CH 3 carboxylic acid in the C(4)R-isomer series significantly increased the α5-subtype selectivity and potency. 27 It was hoped that the acid 6 in the C(4)Sisomer series might affect a similar increase on the selectivity and potency at the α2/α3/α5-subtype. 5b-5e 5b R 2 = CH 2 CH 2 CH 3 (GL-I-32), 82% 5c R 2 = CH(CH 3 ) 2 (GL-I-31), 97% 5d R 2 = C(CH 3 ) 3 (GL-I-30), 96% 5e R 2 = C(CH 3 ) 2 CH 2 CH 3 (GL-I-33), 77% Scheme 3. Synthesis of esters 5b-5e. 40 In a previous study, it was shown that a heteroatom attached directly to the carbonyl at C(3) affects the GABA A R subtype selectivity. For example, a thioester at C(3) in the 2'N series exerted no efficacy at the α1-subtype even at a higher concentration in comparison with the corresponding oxygen substituted ester, but with a slightly higher preference for the α3-subtype. 42 Therefore, it was decided to replace the oxygen atom in lead compound 2 at the C(3) position with a sulfur atom. The thioethyl ester GL-I-77 (7) was synthesized from the carboxylic acid 6 following the general procedure mentioned below (Scheme 4) with ethanethiol as the nucleophile.
Besides the slight changes in steric effects as compared to lead ester 2, amide analogs are well-known stable replacements for labile ester moieties. Amides were considered to be important replacements for ester functions to improve the in vivo stability, as well as the bioavailability when compared to the esters. To evaluate the potential activity of the amides in regard to future SAR, a series of amide analogs 8a-8f were synthesized to enable a comparison between esters and amides in regard to in vitro metabolic stability, cytotoxicity and in vivo locomotor activity. The methyl amide MP-III-023 (8a) was prepared by the direct amidation of ethyl ester 2 in the presence of methylamine in dichloromethane in a sealed tube. As indicated in Scheme 4, the other amide analogs were synthesized from carboxylic acid 6 via an acyl chloride intermediate, using the corresponding primary or secondary amine. This process gave the ethyl amide GL-I-43 (8b), cyclopropyl amide GL-I-55 (8c), isopropyl amide GL-I-57 (8d), t-butyl amide GL-I-41 (8e) and dimethyl amide GL-I-54 (8f), respectively, in good to excellent yields (71-88%). Scheme 4. Synthesis of analogs 5f, 5g, 7, 8a-8f.
Ester bioisosteres have been utilized commonly in drug design in order to render the ester metabolically stable with less adverse effects and provide better clinical candidates. 43 The previous results indicated that replacement of ester functions by substituted 1,2,4-oxadiazoles 36, 44 significantly increased the in vitro and in vivo stability, as well as slightly improved the hydrophilicity of the ligands. 19 Moreover, the efficacy at BZD receptors was enhanced as compared to the corresponding ester ligands. 19 Encouraged by this previous evidence, the substituted 1,2,4-oxadiazoles 9a-9c were designed and synthesized from lead 2. The condensation of the ethyl ester 2 and a corresponding amidoxime in the presence of sodium hydride in THF was employed to prepare the C(3)-substituted oxadiazole ligands. This route had been successfully applied previously with non-chiral ligands. 43 However, the desired oxadiazoles with a C(4) methyl group were obtained only in moderate yields (30-40%). The reason was the formation of a byproduct (50-60% yield), in which the C(5)-C(6) imine bond had isomerized to the C(4)-C(5) position. As a result, the chirality at the C(4) position was lost. To overcome this problem, the amount of sodium hydride, which would readily lead to isomerization of the imine bond, was reduced from 4 equivalents to 1.1 equivalents. In addition, the amidoxime was stirred longer with NaH before the ester was added to the mixture. This process gave methyl oxadiazole GL-I-65 (9a), ethyl oxadiazole GL-I-66 (9b) and isopropyl oxadiazole GL-I-81 (9c) in improved yields of 79-85%, respectively, as depicted in Scheme 5. To explore the extent of flexibility of the hydrogen-bond acceptor in the binding pocket designed H1 in the pharmacophore/receptor model (see Figure S1 in Supplementary material), 22, 36 it was decided to synthesize a linear nitrile at the C(3) position, which has sometimes been employed to increase water solubility of a ligand and has also been used to reduce possible oxidative metabolism by the liver in clinical studies. 45 The nitrile MP-III-018.A (10) The characterization of the lead compound 2 was being carried out simultaneously with the synthesis and assessment of the novel analogs. Due to the ability of 2 to potentiate the α5 containing GABA A R as well as the α2 and α3 subtypes, while inactive at the α1 containing GABA A R, which mediates sedation and other adverse effects, ligand 2 was evaluated in behavioral models in direct comparison with its enantiomer 1. For cataleptic behavior in the schizophrenia studies, 47 the antipsychotic, haloperidol elicited a significant cataleptic response.
In contrast, both C(4)-methyl substituted ligands 1 and 2 did not show any signs of catalepsy in comparison to the vehicle, as illustrated in Figure 3 . Moreover, in the prepulse inhibition (PPI) assay, which was used as a classical animal model of schizophrenia, the S-isomer 2 significantly reversed the PPI deficit induced by phencyclidine hydrochloride (PCP), an N-methyl-D-aspartate (NMDA) antagonist. 48 Ligand 1 antagonized the deficit compared to vehicle but failed to reach a significant effect at the same dosage, as depicted in Figure 4 . However, PPI results with the R-isomer 1 were trending toward significance but would have required a larger number of animals. Additionally, in the 6 Hz electroshock (3 seconds duration) assay, both ligands were evaluated for their ability to protect against epileptic seizures. As shown in Figure 5 , ligand 2 was able to protect mice from the electroshock-induced seizures for all time points (1/4, 1/2, 1, 2, and 4 hours), which was predicted due to the activation of α2 and α3 subtypes ( Figure 5A ) as well as α5 subtypes. However, the Renantiomer (α5) 1 was not effective at any time at a relatively higher dose in the 6 Hz paradigm. For the rotarod (n=8) assay, neither 1 nor 2 produced significant ataxia at 100 mg/kg i.p. in mice ( Figure 5B ). This is in complete agreement with the poor efficacy at α1β3γ2 Bz/GABAergic subtypes previously reported. Rotorod Assay (at 100 mg/kg)
Rotorod Completions (n = 8) Figure 5 . Impact of 1 or 2 treatment on anticonvulsant effects. A) Mice were dosed i.p. with either 1 (150 mg/kg) or 2 (100 mg/kg) and a 6 Hz shock by a corneal electrode was administered at various time points, and the animal observed for convulsions. Ligand 2 was able to protect some subjects while 1 was not able to protect mice from electroshock-induced seizures. B) In the rotarod assay, mice were dosed i.p. with 1 or 2 (100 mg/kg) 30 minutes prior to testing on a rotating rod (6 rpm). Mice that fell 3 times during a 1-minute trial were deemed toxic (ataxic or sedated). (see Supplementary material for details)
The parent compound 2 and its analogs were assayed for metabolic stability in vitro with HLM and mouse liver microsomes (MLM) to identify the most stable analogs and the possible trend of steric effects in respect to stability. Moreover, it was important to evaluate stability in both species with respect to applied animal models and future human treatment with such a diverse array of functional groups at C(3). The results of this study are shown in Table 2 .
The lead compound 2, as mentioned before, was found to be rapidly metabolized on HLM with less than 5% remaining after 20 minutes, while 2 exhibited good stability for MLM with 78% remaining after 1 hour. Among the ester analogs, 3, 4a, 4b, 5a-d, 5f and 5g an increasing trend in metabolic stability in HLM was observed as the size of the alkyl chain increased. However, esters bearing a linear 2-3 carbon chain (4a, 5a, 5b, 5f, and 5g), regardless of the functional group at the C(8) position (-bromo, -cyclopropyl or -ethynyl), were metabolized very rapidly with less than 5% remaining after 10, 20, and 30 minutes in HLM. A similar trend was observed for MLM, however, the C(8)-bromo and -cyclopropyl replacement of the ethynyl group decreased the metabolic stability (see 2 vs 3, 4b; 4a vs 5a). It is important to point out that the introduction of an ester function with a longer carbon side-chain or a terminal CF 3 group reduced the metabolic stability significantly, as shown in Table 1 . Both ligands 4b and 5f could not be detected after 20 minutes in HLM or MLM, respectively. Most of the esters are only slightly more stable in MLM, as compared to HLM, which suggests that longer lipophilic linear alkyl chains in the ester functional group should be avoided in the ligand design. The carboxylic acid 6 was slightly more stable compared to the esters. The stability of thioethyl ester 7 for HLM was improved slightly compared to ethyl ester 2, which suggests that a sulfur atom in place of an oxygen atom would provide greater metabolic stability. Electronegativity might play a role here. The nitrile 10 was metabolized at a rapid rate with only 9% and 16% of 10 remaining after two hours in HLM and MLM, respectively. As expected, the amide analogs remarkably enhanced the metabolic stability in both HLM and MLM. The trend regarding steric effects on the rate of metabolism of the amides was opposite to that of the esters; bulkier substituents were less metabolically stable. Presumably, bulkier esters are more lipophilic and react faster with P450 enzymes in the liver microsomal extract. The ethyl amide 8b exhibited the best stability with more than 92% of 8b remaining after 2 hours, as well as the longest half-life for both types of liver microsomes among all the amides. The isopropyl amide 8d was the only ligand, whose metabolism was a little inconsistent, as a result, the isopropyl ester 5c and amide 8d shared a similar metabolic pattern. As expected, the replacement of the ester moiety with the oxadiazole bioisosteres 9a-9c significantly improved the metabolic stability over a 2-hour period of incubation in both HLM and MLM. It is notable that the isopropyl oxadiazole 9c exhibited the longest half-life (2584 minutes) as compared to all the analogs investigated in the SH-053-2'F-S-CH 3 (2) series. In brief, it is clear that the amides and substituted oxadiazole functionality at the C(3) position provide the desired ligands with longer half-life values, as compared to other functional groups. Further evaluation of these analogs involved a study of potential cytotoxicity in both HEPG2 (liver) and HEK293 (kidney) cell lines, as summarized in Table 3 . a Compounds were incubated at different concentrations with the specific cells for 48 hours, followed by detection of cell viability using a Cell-Titer Glo (Promega). The results were normalized using DMSO (negative control) and 3-dibutylamino-1-(4-hexyl-phenyl)-propan-1-one (150 mM in DMSO final concentration, positive control). Data were acquired by three independent experiments carried out in quadruplet.
C(8)-bromo (see Supplementary material for details)
Examination of the cell viability assay indicated that ligands with a C-3 carboxylic acid substituent of Sisomer analog 6 and dimethyl amide 8f were non-toxic even at 400 µM (LD 50 > 400 μM) in the presence of HEK293 and HEPG2 cells. Compounds C(8)-bromo ethyl ester 4b and trifluoroethyl ester 5f were non-toxic at doses higher than 400 µM (LD 50 > 400 μM) for the HEPG2 cells, and exhibited an LD 50 of 187 µM and 138 µM in HEK293 cells, respectively. Methyl amide 8a showed no toxicity at concentrations below 200 µM for both cell lines. Esters 3, 4a, 5a, 5b, amides 8b-8d, methyl oxadiazole 9a and nitrile 10, were safe at lower concentrations with LD 50 values of >50 μM for both cell lines. Usually, these ligands potentiate the GABA A Rs at nanomolar concentrations, consequently far below the measured LD 50 values of 50 μM. The compounds with moderate cytotoxicity (30 μM <LD 50 <50 μM) were the isopropyl ester 5c, cyclopropyl ester 5g, t-butyl amide 8e and ethyl oxadiazole 9b. Ligands that exhibited pronounced cytotoxicity (LD 50 <30 μM) for HEK293 kidney cells were ethyl ester 2, t-butyl ester 5d, 2-methyl butyl ester 5e, thioethyl ester 7, and isopropyl oxadiazole 9c. These data revealed that increasing the size of the substituent of the oxadiazole moiety may increase cytotoxicity; most of the esters are considered to be cytotoxic if given at very high doses (much higher than any therapeutic doses), unless a different group at C(8) was introduced (see 3, 4a, and 4b). The trifluoroethyl ester was fairly cytotoxic perhaps because the trifluoroethanol group is a much better leaving group. In vitro toxicity can be used as a measure to estimate in vivo toxicity, however, variations can occur. For instance, lead compound 2 exhibited a fairly low LD 50 value, however it was not toxic in a number of pharmacological assays in the mice, rats and primates. [23] [24] [25] [30] [31] [32] The cytotoxicity assays indicated which analogs were least cytotoxic but were not potent enough (nM) to rule out further pharmacological studies in models of schizophrenia or depression.
To assess the possibility of undesired CNS side effects (α1-mediated), a locomotor coordination study of each analog was conducted by placing mice on a rotating rod for a maximum of 3 minutes after oral administration by gavage at a dose of 40 mg/kg ( Figure 6 ). The mice were also observed for loss of righting reflex, an indication of undesired CNS effects. Most of the treated mice exhibited no sedation or ataxia, nor loss of righting reflection vs the control diazepam. Most of the compounds exhibited sensorimotor steadiness at all three time-points, which indicated no sedative/ataxic effects. However, some amides did exbihit some sensorimotor deficits. Methyl amide 8a and ethyl amide 8b effected severe motor impairment, while the cyclopropyl amide 8c and dimethyl amide 8f exhibited only minor impairment. The bulkier isopropyl amide 8d and t-butyl amide 8e did not show any motor impairment. These results suggested that these particular amides, which produced sedation/ataxia, are sedating presumably because of some efficacy at the α1-GABA A R subtype. In regard to the pharmacological effects of the amide side-chain, it is obvious that a smaller alkyl chain promoted a more sedating effect, which should not result from metabolism nor cytotoxicity since these two assays indicated that the amides with smaller substituents were highly stable and non-toxic. After examination of all results for the series of C(4)-S-CH 3 substituted enantiomers described above, the best two compounds, which exhibited excellent stability, minimal or no toxicity and did not exhibit motor impairments, were cyclopropyl amide GL-I-55 (8c) and methyl oxadiazole GL-I-65 (9a). Moreover, it was suggested that the bioisosteres GL-I-66 (9b) and GL-I-81 (9c), which were very metabolically stable and exhibited no sensorimotor impairment, will need to be administrated at low concentrations in behavioral studies to avoid adverse chronic side effects. Amides 8a and 8b exerted excellent stability and no cytotoxicity, however, these two ligands were sedating at 40 mg/kg p.o. Esters (2-5g) including the lead compound 2 exhibited either cytotoxicity or were metabolically less stable in the presence of HLM and MLM. Thioester 7, isopropyl amide 8e and nitrile 10 were not metabolically stable enough to encourage further studies. Carboxylic acid 6 exhibited excellent properties in all three assays, however, the acid functionality will prevent the penetration of the blood brain barrier which was demonstrated for the R enantiomer. 27 This property is not suitable for the treatment of schizophrenia and depression. Cognitive deficits developed in these two disease states are still poorly managed with current drugs. Although the data is only preliminary, S-CH 3 ligand 9a demonstrated procognitive effects (C+) in the Y-maze paradigm. The S-CH 3 ligand 8f was active in the antidepressant assay (forced swim test) and procognitive (A++ and C++) assay. 50 However, 8f was metabolized fairly rapidly in HLM as shown in Table 2 . To date, these two ligands along with 8c in this S-enantiomeric series seemed to be the best candidates for additional preclinical behavioral testing, while in the R-CH 3 series (α5 subtype selective series) a number of ligands have promising pharmacological effects for the treatment of schizophrenia and depression.
Rotarod Testing in Female Swiss
23-25,31,35,50
Conclusions
It is clear that ligand design to target specific GABA A R subtypes without adverse effects is very difficult, in part, due to the absence of a crystal structure of the α 1-6 β 3 γ 2 ion channel, as well as the diversity of the receptor subunit expression in different regions of the brain. Although a crystal structure has been reported for a pentameric GABA ion channel (5 beta subunits form the ion pore), which is an important result going forward, nevertheless, the lack of a benzodiazepine binding site in this structure renders it ineffective for ligand design. 49 In the present research, a number of ligands have been successfully designed and synthesized with the C(4) S-CH 3 stereochemistry. This series of esters, amides, and bioisosteres of the lead compound 2 are devoid of the liable ester functionality at C(3) to enhance metabolic stability. The synthesis of these analogs, importantly, was inexpensive and straightforward with improved yields over the previous routes. 43 More importantly, these reactions can be easily scaled up to gram quantities. The novel ligands 8c and 9a are metabolically stable in the presence of human and mouse liver microsomes and exhibit excellent cytotoxicity (LD 50 ) values. Furthermore, they do not induce sedative effects, which is a major problem of classical benzodiazepine drugs. Taken together, this research of the S-CH 3 enantiomers has provided several novel ligands that possess good safety and metabolic profiles for further in vivo behavioral testing in animal models in both schizophrenia and depression. [23] [24] [25] [31] [32] The in vivo activity of 8c and 9a in models of schizophrenia and depression is ongoing and preliminary studies look very promising.
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Experimental Section
General. Unless specified, all reactions were performed in oven-dried round-bottom flasks or a screw-cap test tube or heavy walled pressure vessel under an argon atmosphere, if required. All organic solvents were anhydrous or purified when necessary by standard methods and purchased from commercial suppliers, as well as all the chemicals. Reactions were monitored by TLC on plates from Dynamic Adsorbents, Inc. under a UV light. The purification of some analogs was completed by flash chromatography on silica gel (230-400 mesh, Dynamic Adsorbents). The melting points were determined on a Stuart melting point SMP3 apparatus manufactured by Barloworld Scientific US Ltd. The optical rotation values were recorded on a Jasco DIP-370 Digital Polarimeter. The I-78, 3) . To a solution of the bromo ethyl ester 4b (5.0 g, 11.3 mmol) in toluene (100 mL) and water (14.5 mL), cyclopropylboronic acid (4.9 g, 57.0 mmol), potassium phosphate (10.3 g, 48.6 mmol) and bis(triphenylphosphine)palladium(II) diacetate (0.85 g, 1.13 mmol) were added under argon. A reflux condenser was attached and the mixture was degassed under vacuum with argon; this process was repeated four times. The mixture was stirred and heated to 100 °C. After 12 h the reaction was completed on analysis by TLC (silica gel) and it was then cooled to rt. Water (10 mL) was added and the mixture was extracted with EtOAc (3 × 15 mL), after which the filtrate was washed with brine (10 mL), dried (Na 2 SO 4 ) and concentrated under reduced pressure. The black residue which resulted was purified by a wash column (silica gel, EtOAc/hexane 7:3) to afford the desired 8-cyclopropyl-imidazobenzodiazepine 3 as a white solid III-059, 4a) . The ethyl ester SH-053-2'F-S-CH 3 2 (2.0 g, 4.52 mmol) was dissolved in methanol (120 mL). Sodium methoxide (0.98 g, 18.1 mmol) was added in one portion and the solution was heated to reflux. The reaction mixture was monitored on analysis by TLC (silica gel, EtOAc/hexane 4:1) until the starting material had been consumed. This took about 30 min. The reaction mixture was cooled to rt and then quenched with a saturated aq solution of NaHCO 3 (20 mL). Water (50 mL) was then added to the solution and the methanol was removed under reduced pressure. The product was extracted with EtOAc (3 x 100 mL) and the organic layers were combined, washed with brine (50 mL) and dried (Na 2 SO 4 ). The solution was concentrated under reduced pressure. The solid, which resulted, was purified by flash column chromatography (silica gel, EtOAc/hexane 4:1) which provided pure methyl ester 4a as an off-white solid ( III-021, 5a) . The ethyl ester SH-053-2'F-S-CH 3 2 (150 mg, 0.387 mmol) was dissolved in MeOH (20 mL). Sodium methoxide (84 mg, 1.55 mmol) was added in one portion and the solution was heated to reflux. The reaction mixture was monitored by analysis by TLC (silica gel, EtOAc/hexane 4:1) until the starting material had been consumed. This took about 30 min. The reaction mixture was cooled to rt and then quenched with a saturated aq solution of NaHCO 3 (4 mL). Water (10 mL) was then added to the solution and the methanol was removed under reduced pressure. The methyl ester 5a was then extracted with EtOAc (3 x 40 mL). The organic layers were combined, washed with brine (10 mL) and dried (Na 2 SO 4 ). The solution was concentrated under reduced pressure. The solid, which resulted, was purified by flash column chromatography (silica gel, EtOAc/hexane 4:1) which provided pure methyl ester 5a as an off-white solid (117 mg, 81% I-32, 5b) . The ester 5b was prepared from 2 following the general procedure for esters with dry 1-propanol. The crude residue was purified by flash column chromatography (silica gel, EtOAc/hexane 7:3) to yield the pure propyl ester 5b as a white powder (0. 17 91 mmol) was dissolved in EtOH (200 mL), after which sodium hydroxide pellets (4.1 g, 103.25 mmol) were added to the solution. This reaction mixture was heated to 55 ˚C for 0.5 h and the EtOH was removed under reduced pressure. The remaining aq solution was stirred at 0 ˚C for 10 min and then aq HCl (1 M) was added dropwise to the solution until the pH was 5 (pH paper). A pale white precipitate which formed, was left in the solution for 10 min and was then collected by filtration, washed with cold water and the aq layer also allowed to stand at rt for 10 h to yield additional acid 6. The combined solids were dried under vacuum for 7 h to provide pure acid 6 as a white powder (4. 2.0 M in toluene) was then added to the solution. The solution was stirred at rt for 5 min and transferred directly for use in the reaction above using a glass syringe and metal needle.
